Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Vertex

How Is Vertex Pharmaceuticals’ Stock Performance Compared to Other Biotech Stocks?

Vertex Pharmaceuticals has outperformed its biotech peers over the past year, yet Wall Street analysts maintain a reasonably optimistic outlook on its future potential.

Barchart

Best Biotech Stocks to Buy in 2025

Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.

MarketBeat

The IT challenge of real-time e-invoicing amid compliance shifts

Kathya Capote Peimbert at Vertex explains the business imperative of real-time e-invoicing amid regulatory changes.

TechRadar

From analysis to the latest developments in health,
read the most diverse news in one place.

Painkillers without the addiction? The new wave of non-opioid pain relief

Pharma firms are developing drugs that avoid the brain’s opioid receptors to minimise the risks of dependence and overdoses, but not all experts are convinced

The Guardian - UK

It's your last chance to buy one of our all-time favorite Shark upright vacuums in the Walmart sale – I'm a vacuum tester, and it's a seriously worthy upgrade

The Shark Vertex DuoClean PowerFin Upright Vacuum is now heavily discounted and brilliant for busy homes

Homes & Gardens

Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?

Vertex Pharmaceuticals has outperformed relative to the healthcare sector over the past year, yet Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

“We’ve never been limited to traditional categories” – Arc'teryx goes all in on technical mountain running shoes for 2025

2025 brings some exciting new technical runners from the Canadian brand, including a running shoe you can climb in

Advnture

Read news from The Economist, FT, and more,
with one subscription

Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?

Vertex Pharmaceuticals has lagged behind the broader market over the past year, and Wall Street analysts are cautiously optimistic about the stock’s future.

Barchart

Is a new painkiller too good to be true?

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids

Salon

FDA approves new type of non-opioid pain medication in two decades

The new drug will be many times more expensive than a standard opioid option

The Independent UK

£1.65m gene-editing therapy offers hope of cure for some blood disorder patients

The treatment uses gene-editing tool Crispr, which earned its inventors the Nobel Prize in chemistry in 2020.

The Independent UK

FDA approves new painkiller that shows promise and challenges of opioid alternatives

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids

The Independent UK

Vertex's Pain Drug: Big Pharma's Next Major Success?

Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.

MarketBeat

Vertex Pharmaceuticals Earnings Preview: What to Expect

With Vertex Pharmaceuticals gearing up to release its fourth-quarter earnings next month, analysts predict a single-digit drop in profit.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

20 innovative breakthroughs that will transform your health

We recognize some of the most staggering, game-changing, life-improving developments of the year.

Benzinga

Decoding 9 Analyst Evaluations For Vertex

During the last three months, 9 analysts shared their evaluations of Vertex (NASDAQ:VERX), revealing diverse outlooks from bullish to bearish.

Benzinga

A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts

In the last three months, 19 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:VRTX), offering a diverse range of perspectives from bullish to bearish.

Barchart

Is Wall Street Bullish or Bearish on Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Vertex Pharmaceuticals Stock Outperforming the Nasdaq?

Vertex Pharmaceuticals has outperformed the Nasdaq over the past year, and analysts remain moderately bullish about the stock's prospects.

Barchart

Are Wall Street Analysts Bullish on Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has outperformed the broader market in 2024 but Wall Street analysts remain cautiously bullish about the stock's potential.

Wallpaper

The British watch brands to know now: from intriguing innovators to heritage revivals

British watch brands are in the ascendant – discover some of the most exciting names and their timepieces

Barchart

Is Vertex Stock Outperforming the S&P 500?

Vertex has outperformed the S&P 500 over the past year, and analysts are moderately bullish on the stock.

Creative Bloq

Vertex 2024 - our best bits and some surprises

We had a blast at Vertex 2024, here are the highlights.

Advnture

Arc’teryx Vertex Alpine GTX approach shoe review: style and performance on above-the-treeline adventures

The close-fitting Arc’teryx Vertex Alpine GTX approach shoe offers reassuring rigidity, protection and grip for battles against gravity

Creative Bloq

Don't miss the chance to get pro tips from ILM concept artist Bimpe Alliu

Improve your portfolio with personalised one-on-one advice.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.